Wide Ranks

IMMX

Immix Biopharma, Inc.

1.97

Top Statistics
Market Cap 54 M Forward PE -3.57 Revenue Growth 0.00 %
Current Ratio 7.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.00 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 23 M Total Cash Per Share 0.8730 Total Debt 1 M
Total Debt To Equity 4.57 Current Ratio 7.00 Book Value Per Share 0.8230
All Measures
Short Ratio 294.00 % Message Board Id finmb_417356223 Shares Short Prior Month 552754
Return On Equity -1.04 City Los Angeles Uuid a16f90b7-2d1a-3bc1-ad13-b52d1a275ae3
Previous Close 1.65 First Trade Date Epoch Utc 1 B Book Value 0.8230
Beta 0.1040 Total Debt 1 M Volume 698475
Price To Book 2.39 Fifty Two Week Low 1.26 Total Cash Per Share 0.8730
Shares Short Previous Month Date 1 B Target Median Price 7.00 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 7.00 Net Income To Common -19022096
Short Percent Of Float 0.0507 Implied Shares Outstanding 27 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 258960 Average Volume10days 258960
Total Cash 23 M Next Fiscal Year End 1 B Held Percent Insiders 0.4010
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.65 Target Low Price 7.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.62 Open 1.61 Free Cashflow -8693799
State CA Dividend Yield 0.00 % Return On Assets -0.5685
Time Zone Short Name EST Trailing Eps -0.8400 Day Low 1.60
Address1 11400 West Olympic Boulevard Shares Outstanding 27 M Price Hint 4
Target High Price 7.00 Website https://www.immixbio.com 52 Week Change -0.6145
Average Volume 132598 Forward Eps -0.5500 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 665.20 % Is_sp_500 False
Regular Market Day High 2.20 Profit Margins 0.00 % Debt To Equity 4.57
Fifty Two Week High 7.75 Day High 2.20 Shares Short 434935
Regular Market Open 1.61 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0158 Operating Cashflow -14846913
Currency USD Time Zone Full Name America/New_York Market Cap 54 M
Is_nasdaq_100 False Zip 90064 Quote Type EQUITY
Industry Biotechnology Long Name Immix Biopharma, Inc. Regular Market Day Low 1.60
Held Percent Institutions 0.1764 Current Price 1.97 Address2 Suite 200
Enterprise To Ebitda -1.00 Financial Currency USD Current Ratio 7.00
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country United States
Float Shares 14 M Two Hundred Day Average 2.19 Enterprise Value 20 M
Forward PE -3.57 Regular Market Volume 698475 Ebitda -20180932
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia.

The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma.

It has a clinical collaboration and supply agreement with BeiGene Ltd.

for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.

Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.